Healthcare / Medical DevicesNasdaqCM
$12.64
-0.03 (-0.24%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-14.8M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$379M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-91.1%
↓Gross Margin
61.4%
↑Debt/Equity
2.08
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
+19.2%
FCF CAGR
—
FCF margin
-66.1%
FCF / Net income
0.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $37.0M · net income $-25.5M · FCF $-24.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $37.0M | $37.0M | $31.4M | $24.0M | $20.6M | $16.3M | $12.8M | $11.2M | $7.4M | $7.4M | $5.7M | $4.6M | $3.6M | $3.9M | $5.1M | $3.8M | $2.7M |
| Net Income | $-25.5M | $-25.5M | $-18.9M | $-22.1M | $-16.4M | $-14.4M | $-6.8M | $-5.5M | $-6.2M | $-7.2M | $-8.1M | $-8.4M | $-4.5M | $-7.1M | $-5.9M | $-8.3M | $-9.5M |
| EBITDA | $-20.9M | $-20.9M | $-16.5M | $-21.0M | $-15.6M | $-13.2M | $-5.9M | $-4.5M | $-5.1M | $-6.2M | $-7.3M | $-8.8M | $-4.9M | $-7.0M | $-2.7M | $-5.6M | $-9.2M |
| EPS | — | — | -0.70 | -0.90 | -0.68 | -0.69 | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 61.4% | 61.4% | 60.9% | 56.8% | 65.8% | 68.2% | 71.1% | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -65.4% | -65.4% | -62.9% | -93.7% | -79.5% | -82.1% | -48.5% | -41.0% | -71.4% | -85.9% | -130.3% | -195.3% | -147.6% | -190.2% | -61.9% | -155.1% | -356.5% |
| Net Margin | -69.1% | -69.1% | -60.3% | -92.2% | -80.0% | -88.4% | -52.9% | -49.4% | -83.8% | -97.1% | -140.4% | -183.9% | -125.5% | -180.3% | -116.2% | -217.7% | -354.2% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 2.08 | 2.08 | 0.14 | 0.66 | 0.32 | 0.20 | 8.95 | 0.45 | 2.31 | 0.84 | -5.94 | -4.10 | -109.78 | — | — | — | — |
| Current Ratio | 5.79 | 5.79 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-24.4M | $-24.4M | $-9.2M | $-14.8M | $-17.3M | $-12.9M | $-7.8M | $-2.9M | $-4.7M | $-6.0M | $-5.9M | — | $-7.3M | $-7.9M | $-7.6M | $-6.3M | $-7.8M |
| Returns | |||||||||||||||||
| ROE | -91.1% | -91.1% | -74.5% | -104.3% | -44.6% | -29.5% | -285.3% | -120.8% | -408.2% | -123.0% | 1067.3% | 426.5% | 4509.8% | 103.7% | 74.7% | 38.1% | 61.6% |
| Valuation | |||||||||||||||||
| P/B | 13.25 | 13.25 | 16.92 | 7.08 | 5.47 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 17.8% | 17.8% | 31.0% | 16.6% | — | 27.0% | 14.4% | 52.5% | -0.4% | 28.4% | 25.1% | 27.5% | -8.3% | -22.3% | 32.5% | 43.0% | — |
| EPS Growth | — | — | 22.2% | -32.4% | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.70 → n/d
Residual
+7.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.